Starling Oncology, Inc.
TOIFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Starling Oncology, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 24, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| ProShare Advisors LLC | 2026-03-31 | 11,561 | $35.5K | SEC filing |
| INTECH INVESTMENT MANAGEMENT LLC | 2026-03-31 | 22,482 | $69K | SEC filing |
| Kanen Wealth Management LLC | 2026-03-31 | 2,777,858 | $8.53M | SEC filing |
| WEXFORD CAPITAL LP | 2026-03-31 | 1,711,323 | $5.25M | SEC filing |
| Sterling Capital Management LLC | 2026-03-31 | 518 | $1.59K | SEC filing |
| US BANCORP \DE\ | 2026-03-31 | 96 | $295 | SEC filing |
| Balyasny Asset Management L.P. | 2026-03-31 | 1,826,370 | $5.61M | SEC filing |
| TWO SIGMA INVESTMENTS, LP | 2026-03-31 | 307,754 | $945K | SEC filing |
| Dauntless Investment Group, LLC | 2026-03-31 | 462,057 | $1.42M | SEC filing |
| AQR CAPITAL MANAGEMENT LLC | 2026-03-31 | 44,519 | $137K | SEC filing |
| ALLIANCEBERNSTEIN L.P. | 2026-03-31 | 61,600 | $219K | SEC filing |
| MARSHALL WACE, LLP | 2026-03-31 | 342,265 | $1.05M | SEC filing |
| R Squared Ltd | 2026-03-31 | 16,353 | $50.2K | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 171,940 | $528K | SEC filing |
| Schonfeld Strategic Advisors LLC | 2026-03-31 | 21,234 | $65.2K | SEC filing |
| TIFF ADVISORY SERVICES, LLC | 2026-03-31 | 195,469 | $565K | SEC filing |
| Centiva Capital, LP | 2026-03-31 | 224,245 | $688K | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 1,757,847 | $5.4M | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 4,992 | $15.3K | SEC filing |
| FMR LLC | 2026-03-31 | 49,531 | $152K | SEC filing |
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Pekin Hardy Strauss, Inc.: 10,000 shares reported 2025-12-31; 32,000 shares reported 2026-03-31.
- GROUP ONE TRADING LLC: 62,140 shares reported 2025-12-31; 9,038 shares reported 2026-03-31.
- Holt Capital Advisors, L.L.C. dba Holt Capital Partners, L.P.: 29,534 shares reported 2025-12-31; 29,534 shares reported 2026-03-31.
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC: 208,265 shares reported 2025-12-31; 214,915 shares reported 2026-03-31.
- TWO SIGMA INVESTMENTS, LP: 262,050 shares reported 2025-12-31; 307,754 shares reported 2026-03-31.
- Sterling Capital Management LLC: 390 shares reported 2025-12-31; 518 shares reported 2026-03-31.
- INTECH INVESTMENT MANAGEMENT LLC: 17,722 shares reported 2025-12-31; 22,482 shares reported 2026-03-31.
106 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Starling Oncology, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2024-11-26 · Hively Brad: Larger than all 9 other insider purchases of Common stock on file. SEC filing
- 2022-11-11 · Havencrest Healthcare Partners, L.P.: Larger than all 12 other insider sales of Common stock on file. SEC filing
- 2022-11-10 · Havencrest Healthcare Partners, L.P.: Larger than 11 of the 12 other insider sales of Common stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-23 | Chernett Jorey · 10% owner | Common Stock | P — Open market or private purchase | +18,000 | 5.02 | SEC filing |
| 2026-06-08 | Podnos Yale · Chief Medical Officer | Common Stock | S — Open market or private sale | −23,451 | 5.38 | SEC filing |
| 2026-06-04 | Chernett Jorey · 10% owner | Common Stock | P — Open market or private purchase | +12,000 | 4.75 | SEC filing |
| 2026-05-20 | Chernett Jorey · 10% owner | Common Stock | P — Open market or private purchase | +33,500 | 4.07 | SEC filing |
| 2026-05-19 | Chernett Jorey · 10% owner | Common Stock | P — Open market or private purchase | +30,000 | 4.09 | SEC filing |
| 2026-05-19 | Chernett Jorey · 10% owner | Common Stock | P — Open market or private purchase | +5,000 | 4.05 | SEC filing |
| 2026-04-16 | Kaushal Mohit · Director | Common Stock | S — Open market or private sale | −38,433 | 3.50 | SEC filing |
| 2026-04-14 | Kaushal Mohit · Director | Common Stock | S — Open market or private sale | −57,286 | 3.50 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-03-27 | England Kristin · Chief Administrative Officer | Common Stock | A — Grant, award, or other acquisition | +55,743 | SEC filing |
| 2026-03-27 | Podnos Yale · Chief Medical Officer | Common Stock | A — Grant, award, or other acquisition | +66,446 | SEC filing |
| 2026-03-27 | Virnich Daniel · Chief Executive Officer | Common Stock | A — Grant, award, or other acquisition | −670,608 | SEC filing |
| 2026-03-27 | Langsam Jeffrey · Chief Clinical Officer | Common Stock | A — Grant, award, or other acquisition | +70,270 | SEC filing |
| 2026-03-27 | Carter Robert Ross · Chief Financial Officer | Common Stock | A — Grant, award, or other acquisition | −202,914 | SEC filing |
| 2025-11-20 | McGeorge Anne · Director | Common Stock | A — Grant, award, or other acquisition | +67,901 | SEC filing |
| 2025-11-20 | Ling Gabriel · Director | Common Stock | A — Grant, award, or other acquisition | +37,037 | SEC filing |
| 2025-11-20 | Hively Brad · Director | Common Stock | A — Grant, award, or other acquisition | +32,407 | SEC filing |
Showing 8 of 21 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-21 | Virnich Daniel · Chief Executive Officer | Common Stock | J — Other acquisition or disposition | −23,058 | SEC filing |
| 2026-05-21 | Podnos Yale · Chief Medical Officer | Common Stock | J — Other acquisition or disposition | −1,805 | SEC filing |
| 2026-05-21 | Carter Robert Ross · Chief Financial Officer | Common Stock | J — Other acquisition or disposition | −1,604 | SEC filing |
| 2026-03-27 | Podnos Yale · Chief Medical Officer | Common Stock | J — Other acquisition or disposition | −16,173 | SEC filing |
| 2026-03-27 | Virnich Daniel · Chief Executive Officer | Common Stock | J — Other acquisition or disposition | −98,534 | SEC filing |
| 2026-03-27 | Carter Robert Ross · Chief Financial Officer | Common Stock | J — Other acquisition or disposition | −20,320 | SEC filing |
| 2026-03-17 | Virnich Daniel · Chief Executive Officer | Common Stock | J — Other acquisition or disposition | −11,834 | SEC filing |
| 2026-03-17 | Podnos Yale · Chief Medical Officer | Common Stock | J — Other acquisition or disposition | −3,420 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.